EPM speaks to Rafael Teixeira, President of logistics suppliers World Courier and ICS about the challenges of distributing a Covid-19 vaccine after approval.
EPM speaks to Chris Ross, head of Life Science Integrated Supply Chain Operations at Merck to discuss the company's response to Covid-19 and the challenges in developing and supplying vaccines.
David Knight, partner and Joshua Marshall, senior associate at Fieldfisher discuss the implications the Covid-19 Technology Access Pool is having on innovation in pharma.
Dr Clive Glover, director, strategy at Pall Corporation, discusses the steps the pharmaceutical industry has taken to speed up the development of a Covid-19 vaccine.
Contract development and manufacturing organisation (CDMO) Cobra Biologics and the Karolinska Institutet (KI) have been awarded €3 million in emergency funding to take a DNA vaccine for Covid-19 through phase I clinical trial testing.
EPM speaks to Nigel Theobald, CEO of N4 Pharma who discusses the formulation challenges that can occur during drug development and what the company is doing to improve vaccine delivery systems.
Dr Neil Polwart, Novarum founder and BBI Group head of Mobile, discusses the role technology plays in stopping preventable diseases spreading across the world.
In this online exclusive, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), looks at the importance of vaccines in the fight against antimicrobial resistance (AMR).
